Journal Mobile Options
Table of Contents
Vol. 24, No. 1-2, 2005
Issue release date: December 2004
Neuroepidemiology 2005;24:15–21
(DOI:10.1159/000081044)

Epidemiological Study of Creutzfeldt-Jakob Disease Death Certificates in Canada, 1979–2001

ElSaadany S. · Semenciw R. · Ricketts M. · Mao Y. · Giulivi A.
aStatistics and Risk Assessment Section, bBlood Safety Surveillance and Health-Care Acquired Infections Division, Centre for Infectious Disease Prevention and Control, cSurveillance and Risk Assessment Division, Centre for Chronic Disease Prevention and Control, Population and Public Health Branch, Health Canada, Ottawa, Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Introduction: A descriptive epidemiological analysis to update trends of Creutzfeldt-Jakob disease (CJD) deaths, from 1979–2001, was undertaken. Methods: Cases with CJD as underlying cause were extracted. Age-adjusted death rates by age, sex, and province were calculated. Information on birthplace, autopsy indications and type of work were examined for death certificates from 1979 to 1997. Results: 462 cases were identified between 1979 and 1997. The average annual age-standardized mortality rate was 0.93 deaths per million persons during this period and 1.03 for 1998–2001. Persons 60 years or older demonstrated the highest average annual mortality rate. Rates were slightly higher among males and increased with age. Persons born in Canada accounted for 72% of deaths. Cause of death was verified by autopsy for 9.1% of patients while 21% of deaths indicated that additional information relating to underlying cause was expected. The service industry occupation represented the largest mortality (Quebec does not capture these data). Conclusions: Canadian rates are consistent with those of the United States and slightly higher than those of certain European countries. Approximately 44% of CJD cases had an autopsy record, though many were incomplete. We are unable to determine a relation with occupation. We recommend annual analysis of CJD death registrations for updated surveillance of trends, as mortality data are an efficient tool for monitoring incidence.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Brown P, Cathala F, Raubertas RF, Gajdusk DC, Castaigne P: The epidemiology of Creutzfeldt-Jakob disease: Conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987;37:895–904.
  2. Masters CL, Gajdusek DC, Gibbs CJ Jr: The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer’s disease. Brain 1981;104:535–558.
  3. Masters CL, Harris JO, Gajdusek DC, Gibs CJ Jr, Bernoulli C, Asher DM: Creutzfeldt-Jakob disease: Pattern of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177–188.
  4. Goldfarb LG, Brown P, Mitrova E, Cervenakova L, Goldin L, Korczyn AD, et al: Creutzfeldt-Jakob disease associated with the PRNP codon 200LYS mutation: An analysis of 45 families. Eur J Epidemiol 1991;7(5):477–486.
  5. Nosal R, Kapoor A, Shanin R: Cluster of Cases of Creutzfeldt-Jakob Disease-Ontario. Canadian Disease Weekly Report, 17–3:12 pp., January 19, 1991.
  6. Thadani V, Penar PL, Partingon J, Kalb R, et al: Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. J Neurosurg 1988;69:766–769.
  7. Masullo C, Pocchiari M, Macche G, Alema G, Piazza G, Panmzera MA: Transmission of Creutzfeldt-Jakob disease by dural cadaveric graft. J Neurosurg 1989;71:954–955.
  8. Nisbet TJ, MacDonaldson I, Bishara SN: Creutzfeldt-Jakob disease in a second patient who received a cadaveric dura mater graft. JAMA 1989;261:1118.

    External Resources

  9. Miyashita K, Inuzuka T, Kondo H, Saito Y, Fujita N, Matsubara N, et al: Creutzfeldt-Jakob disease in a patient with a cadaveric dural graft. Neurology 1991;41:940–941.
  10. Willison HJ, Gale AN, Mcluaghlin JE: Creutzfeldt-Jakob disease following cadaveric dura mater graft. J Neurol Neurosurg Psychiatry 1991;54:940.
  11. Pocchiari M, Masullo C, Salvatore M, Genuardi M, Galgani S: Creutzfeldt-Jakob disease after non-commercial dura mater graft. Lancet 1992;340:614–615.
  12. Esmonde T, Lueck CJ, Symon L, Duchen LW, Will RG: Creutzfeldt-Jakob disease and lyophilised dura mater grafts: report of two cases. J Neurol Neurosurg Psychiatry 1993;56:999–1000.
  13. Lane KL, Brown P, Howell DN, et al: Creutzfeldt-Jakob disease in a pregnant woman with an implanted dura mater graft. Neurosurgery 1994;34:737–740.
  14. Martinez-Lage JF, Poza M, Sola J, Totosa JG, Brown P, et al: Accidental transmission of Creutzfeldt-Jakob disease by dural cadaveric grafts. J Neurol Neurosurg Psychiatry 1994;57:1091–1094.
  15. Yamada S, Aiba Y, Endo Y, Hara M, Kitamoto T, Tateishi J: Creutzfeldt-Jakob disease transmitted by a cadaveric dura mater graft. Neurosurgery 1994;34:740–744.
  16. Lang CJG, Schuler P, Engelhardt A, Spring A, Brown P: Probable Creutzfeldt-Jakob disease after a cadaveric dural graft. Eur J Epidemiol 1995;11(1):79–81.
  17. Brown P: Environmental causes of human spongiform encephalopathy; in Baker HF, Ridley RM (eds): Prion Diseases. Methods in Molecular Medicine. Totowa, NJ, Humana Press, 1996, pp 139–154.
  18. Health Canada: First Canadian Case of Variant Creutzfeldt-Jakob Disease (vCJD). Health Canada Online: Keeping You Informed. May 2003. http://www.hc-sc.gc.ca/english/disease/cjd/index.html.
  19. Saskatchewan Government: Rare Disease Not a Public Threat. Media Services News Release, August 2002. http://www.gov.sk.ca/newsrel/release/2002/08–636.html.
  20. Ehman AJ: Threat from Canada’s first vCJD case Minimal: Nouvelles, Saskatoon. CMAJ 2002;167:680.
  21. WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. Report of a WHO Consultation. World Health Organization, Geneva, March 1999.
  22. Stratton E, Ricketts MN, Gully PR: Creutzfeldt-Jakob disease in Canada. Canada Comm Dis Report – 15 Apr 1996;22–8. http://www.hc-sc.gc.ca/hpb/lcdc/publicat/ccdr/96vol22/dr2208ea.html.
  23. Gibbons RV, Holman RC, Belay ED, Schonberger LB: Creutzfeldt-Jakob disease in the United States: 1979–1998. JAMA 2000;284 (18):2322–2323.
  24. Health Canada: Blood Borne Pathogens Routine Surveillance System Report, Vol 1, Issue 1. Statistics and Risk Assessment Section, Blood-Borne Pathogens Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2001.
  25. Holman RC, Khan AS, Kent J, et al: Epidemiology of Creutzfeldt-Jakob disease in the United States, 1979–1990: Analysis of national mortality data. Neuroepidemiology 1995;14:174–181.
  26. Tan L, Williams MA, Khan MK, et al: Risk of transmission of bovine spongiform encephalopathy to humans in the United States. JAMA 1999;281:2330–2339.
  27. Creutzfeldt-Jakob Disease Surveillance System (CJD-SS). Prions Section, Blood Borne Pathogens Division. Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada. http://www.hc-sc.gc.ca/hpb/lcdc/bid/bbp/cjd/index.html.
  28. Davanipour Z, Smoak C, Bohr T, et al: Death certificates: an efficient source for ascertainment of Creutzfeldt-Jakob disease cases. Neuroepidemiology 1995;14:1–6.
  29. World Health Organization: International classification of diseases: Manual of the international statistical classification of diseases, injuries, and causes of death, 9th revision. Geneva, WHO, 1979.
  30. Breslow N, Day N: The Design and Analysis of Cohort Studies, vol 2. IARC Scientific Publication No. 82, International Agency for Research on Cancer, Lyon, 1987.
  31. Statistics Canada: Annual demographic statistics 2001. Demography Division, Catalogue 91–213-XPB, Annual, Ottawa, 2003.
  32. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (eds): SEER Cancer Statistics Review, 1975–2000, National Cancer Institute. Bethesda, MD, 2003. http://seer.cancer.gov/csr/1975_2000.
  33. Statistics Canada: 1996 Census of Canada, The Nation Series, ed. 1: Demographic Information, Families: Number, Type and Structure, Structural Type of Dwelling and Household Size, Immigration and Citizenship, Package No. 3: Immigration and Citizenship. Ottawa, 1997. Catalogue No. 93F0020XCB96001.
  34. Statistics Canada, Standard Occupational Classification (catalogue # 12-565-XPE80001), 1980.
  35. 1996 Census of Canada. The Nation Series, ed 3: Labour Force 15 Years and Over by Detailed Occupation. Statistics Canada, 1993. Catalogue No. 93F0020XCB.
  36. Holman RC, Khan AS, Belay ED, Schonberger LB: Creutzfeldt-Jakob disease in the United States, 1979–1994. Emerg Infect Dis 1996;2:333–337.
  37. Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E, de Silva R, D’Alessandro M, Delasnerie-Laupretre N, Zerr I, van Duijn C, for the Collaborative Study Group for CJD: Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993–1995. Ann Neurol 1998;43:763–767.
  38. Cousens SN, Harries-Jones R, Knight R, et al: Geographical distribution of cases of Creutzfeldt-Jakob disease in England and Wales 1970–1984. J Neurol Neurosurg Psychiatry 1990;53:459–465.
  39. Brown P, Cathala F, Raubertas RF, et al: The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987;37:895–904.
  40. Alderson MR: Some sources of error in British occupational mortality data. Br J Ind Med 1972;29(3):245–254.
  41. Petersen GR, Milham S Jr: Hodgkin’s disease mortality and occupational exposure to wood. J Natl Cancer Inst 1974;53(4):957–958.
  42. Milham S Jr, Strong TR: Human arsenic exposure in relation to a copper smelter. Env Res 1974;7:176–182.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50